Allogene Therapeutics (ALLO)

[jondoeuk]

An internal program (to overcome rejection) will downregulating MHC Class I expression and adding an NK cell inhibitory receptor antibody. Also, improvements are being made to the ex vivo expansion, with the use of defined populations of T-cells, of certain phenotypes (this achieved with cytokines and/or an anti-CD3/CD28 nanomatrix). In addition, RNAi to inhibit certain activity, such as EBAG9, which increases the release of cytolytic granules and/or granzyme- containing secretory lysosomes.